Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GSK Touts New Study Results for COPD Drug

By Ryan Bushey | September 8, 2016

GlaxoSmithKline (GSK) could have an early advantage in the race to refine a potent inhaler for treating chronic obstructive pulmonary disease (COPD).

The company announced results from a Phase 3b study testing an experimental three-in-one drug on an estimated 2,802 patients at about 80 primary care sites in England. There was no predetermined criterion for patients to enroll in this study, which is why all volunteers came from a broad demographic.

Investigators in charge of this study were tasked with following patients for a total of 12 months. A single electronic medical record linking primary care, secondary care, and pharmacy data was used to monitor patients throughout the study. Participants were allowed to change or modify treatments during this period at any time. All of this was designed to track the rate of exacerbations during treatment, which is a trigger that worsens COPD symptoms.

Patients taking the triple therapy for a 24-week period experienced about 35 percent fewer moderate to severe flare-ups from the disease, reported Reuters. This was compared to AstraZeneca’s two-in-one treatment Symbicort. Another subset of patients saw 44 percent reduction in exacerbations in up to 52 weeks.

GSK is working on this drug with another company Innoviva. The organizations announced that this clinical trial met its goal in June, but this data regarding exacerbations was revealed at the recent European Respiratory Society Congress in London.

This particular therapy fuses drugs fluticasone, umeclidinium and vilanterol together with the intent of using three different mechanisms to open the airways of patients with the more severe version of this ailment, wrote Reuters.

A filing for regulatory approval could happen later this year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE